FDA Approved: PYLARIFY — Original Application (Progenics Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approves PYLARIFY (piflufolastat F-18) as an original NDA for PET imaging to detect suspected recurrent prostate cancer in adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Pylarify (piflufolastat F-18)

Snippet

ORIG AP for PYLARIFY (PIFLUFOLASTAT F-18)